Investigating New Cancer Treatment Options
to Improve Patients’ Lives

Clinical
Trials

Immune Design is developing first-in-class immuno-oncology drug candidates designed to make a meaningful difference for cancer patients. Below, please find a list of our current clinical trials.

 

 

SYNOVIAL SARCOMA: CMB305

Title: A Phase 3, Randomized, Double Blind, Placebo Controlled Study to Determine the
Efficacy and Safety of CMB305 in Unresectable Locally Advanced or Metastatic NY ESO 1+ Synovial Sarcoma Subjects Following First Line Systemic Anti Cancer Therapy (Synovate Study)

Summary: To assess if the CMB305 vaccine regimen may help the body’s immune system to slow or stop the growth of synovial sarcoma tumor and improve survival.

Status: Recruiting

More Information: Visit www.synovatestudy.com or clinicaltrials.gov identifier: NCT03520959

ADVANCED, RELAPSED OR METASTATIC SARCOMA: CMB305

Title: A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1

Objective: Evaluate the safety and clinical efficacy of CMB305 in combination with atezolizumab versus atezolizumab alone in patients with locally advanced, relapsed, or metastatic synovial sarcoma or myxoid/round-cell liposarcoma expressing the NY-ESO-1 cancer testis antigen.

Status: Active/Not Recruiting

More Information: clinicaltrials.gov identifier: NCT02609984.

NY-ESO-1 Expressing Cancers: CMB305

Title: A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Objective: Evaluate the safety and tolerability, immunogenicity, and preliminary clinical efficacy of CMB305 in patients with locally advanced, relapsed or metastatic solid cancers, whose tumors express NY-ESO-1.

Status: Recruiting

More Information: clinicaltrials.gov identifier: NCT0237125

Follicular Non-Hodgkin’s Lymphoma: G100

Title: Phase 1/2 Study of Intratumoral G100 Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma

Objective: To evaluate the safety and tolerability of ascending doses of intratumoral G100 in patients with follicular non-Hodgkin’s lymphoma (NHL) receiving local radiation

Status: Active/Not Recruiting

More Information: clinicaltrials.gov identifier: NCT02501473